Human 4-1BB (CD137) signals are mediated by TRAF2 and activate nuclear factor-kappa B - PubMed (original) (raw)
. 1998 Jan 26;242(3):613-20.
doi: 10.1006/bbrc.1997.8016.
Affiliations
- PMID: 9464265
- DOI: 10.1006/bbrc.1997.8016
Human 4-1BB (CD137) signals are mediated by TRAF2 and activate nuclear factor-kappa B
I K Jang et al. Biochem Biophys Res Commun. 1998.
Abstract
Human 4-1BB (CD137), a member of the tumor necrosis factor receptor (TNFR) superfamily, costimulates T cell activation. No apparent intrinsic kinase activity is seen with 4-1BB, which suggests that 4-1BB-associated molecules may be involved in 4-1BB-mediated signal transduction. We found that tumor necrosis factor receptor-associated factor (TRAF) 1, TRAF2, and TRAF3, all interacted with the cytoplasmic domain of 4-1BB. Mutation analysis showed that TRAF1, TRAF2, and TRAF3 were associated with one of two runs of acidic residues found in the cytoplasmic domain of 4-1BB. In addition, 4-1BB cross-linking with TCR signal in Jurkat cells and overexpression of 4-1BB in 293 cells were able to induce activation of the nuclear factor-kappa B (NF-kappa B). 4-1BB-mediated NF-kappa B activation was inhibited by a dominant negative-TRAF2 or -NF-kappa B-inducing kinase (NIK). These data suggest that 4-1BB functions may be mediated by NF-kappa B activation, which requires a TRAF2/NIK pathway.
Similar articles
- CD40-tumor necrosis factor receptor-associated factor (TRAF) interactions: regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization.
Pullen SS, Miller HG, Everdeen DS, Dang TT, Crute JJ, Kehry MR. Pullen SS, et al. Biochemistry. 1998 Aug 25;37(34):11836-45. doi: 10.1021/bi981067q. Biochemistry. 1998. PMID: 9718306 - TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs.
Hauer J, Püschner S, Ramakrishnan P, Simon U, Bongers M, Federle C, Engelmann H. Hauer J, et al. Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2874-9. doi: 10.1073/pnas.0500187102. Epub 2005 Feb 11. Proc Natl Acad Sci U S A. 2005. PMID: 15708970 Free PMC article. - Tumor necrosis factor alpha-induced activation of c-jun N-terminal kinase is mediated by TRAF2.
Reinhard C, Shamoon B, Shyamala V, Williams LT. Reinhard C, et al. EMBO J. 1997 Mar 3;16(5):1080-92. doi: 10.1093/emboj/16.5.1080. EMBO J. 1997. PMID: 9118946 Free PMC article. - Role of 4-1BB in immune responses.
Vinay DS, Kwon BS. Vinay DS, et al. Semin Immunol. 1998 Dec;10(6):481-9. doi: 10.1006/smim.1998.0157. Semin Immunol. 1998. PMID: 9826581 Review. - Role of 4-1BB:4-1BB ligand in cancer immunotherapy.
Cheuk AT, Mufti GJ, Guinn BA. Cheuk AT, et al. Cancer Gene Ther. 2004 Mar;11(3):215-26. doi: 10.1038/sj.cgt.7700670. Cancer Gene Ther. 2004. PMID: 14671675 Review.
Cited by
- Apoptosis and genes involved in oral cancer - a comprehensive review.
Dwivedi R, Pandey R, Chandra S, Mehrotra D. Dwivedi R, et al. Oncol Rev. 2020 Jul 9;14(2):472. doi: 10.4081/oncol.2020.472. eCollection 2020 Jul 6. Oncol Rev. 2020. PMID: 32685111 Free PMC article. - 4-1BB enhancement of CAR T function requires NF-κB and TRAFs.
Li G, Boucher JC, Kotani H, Park K, Zhang Y, Shrestha B, Wang X, Guan L, Beatty N, Abate-Daga D, Davila ML. Li G, et al. JCI Insight. 2018 Sep 20;3(18):e121322. doi: 10.1172/jci.insight.121322. eCollection 2018 Sep 20. JCI Insight. 2018. PMID: 30232281 Free PMC article. - Boosting Antitumor Response by Costimulatory Strategies Driven to 4-1BB and OX40 T-cell Receptors.
Mascarelli DE, Rosa RSM, Toscaro JM, Semionatto IF, Ruas LP, Fogagnolo CT, Lima GC, Bajgelman MC. Mascarelli DE, et al. Front Cell Dev Biol. 2021 Jun 30;9:692982. doi: 10.3389/fcell.2021.692982. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34277638 Free PMC article. Review. - The pharmacology of second-generation chimeric antigen receptors.
van der Stegen SJ, Hamieh M, Sadelain M. van der Stegen SJ, et al. Nat Rev Drug Discov. 2015 Jul;14(7):499-509. doi: 10.1038/nrd4597. Nat Rev Drug Discov. 2015. PMID: 26129802 Free PMC article. Review. - 4-1BB: A promising target for cancer immunotherapy.
Kim AMJ, Nemeth MR, Lim SO. Kim AMJ, et al. Front Oncol. 2022 Sep 14;12:968360. doi: 10.3389/fonc.2022.968360. eCollection 2022. Front Oncol. 2022. PMID: 36185242 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous